Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Releasing IoM Drug Safety Report Could Be Early On Von Eschenbach’s Watch

This article was originally published in The Tan Sheet

Executive Summary

One of Andrew von Eschenbach's first major steps as FDA commissioner will likely be a release of the agency task force response to the Institute of Medicine's (IoM) recommendations to improve drug safety oversight

You may also be interested in...



Von Eschenbach Confirmation Clears Holds At Tail-End Of Lame Duck

Andrew von Eschenbach's nomination to be FDA commissioner cleared the Senate by a comfortable 80-11 margin on Dec. 7, ending months of "holds" on the vote and opposition from both sides of the aisle

Congressional Oversight “Misunderstood” By Von Eschenbach – Grassley

Continued criticism of FDA Acting Commissioner Andrew von Eschenbach by Senate Finance Committee Chairman Charles Grassley (R-Iowa) suggests that chances of a Senate vote on the nominee as full commissioner during Congress' lame-duck session have not brightened

Sweeping Changes At CDER Recommended In IoM Drug Safety Report

FDA's Center for Drug Evaluation & Research is "an organization in urgent need of great change," the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee concludes in a Sept. 22 final report

Related Content

Topics

UsernamePublicRestriction

Register

PS100057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel